Watchlist Price Alert

Intellia Therapeutics Inc... (NTLA)

NASDAQ: NTLA · Real-Time Price · USD

8.34

-0.21 (-2.46%)

At close: May 13, 2025, 3:59 PM

8.39

0.66%

After-hours: May 13, 2025, 07:58 PM EDT

-2.46% (1D)

Bid	8.27
Market Cap	863.36M
Revenue (ttm)	57.88M
Net Income (ttm)	-519.02M
EPS (ttm)	-5.25
PE Ratio (ttm)	-1.59
Forward PE	-1.94
Analyst	Buy

Ask	8.39
Volume	2,920,534
Avg. Volume (20D)	3,582,548
Open	8.56
Previous Close	8.55
Day's Range	8.01 - 8.74
52-Week Range	5.90 - 28.18
Beta	2.33

About NTLA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol NTLA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for NTLA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Intellia Therapeutics has released their quartely earnings on May 8, 2025:

Revenue of $16.63M exceeds estimates by $4.64M, with -42.54% YoY decline.

EPS of -1.1 exceeds estimates by 0.17, with 1.79% YoY growth.

Why Price Moved

6 days ago

+13.58%

Intellia Therapeutics shares are trading higher af... Unlock content with Pro Subscription

2 months ago

-7.09%

Intellia Therapeutics shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and cut its price target from $45 to $13. Additionally, Chardan Capital lowered its price target from $91 to $68.

News

1 day ago · seekingalpha.com

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

Investors who've been looking for problems at Intellia Therapeutics have, during the past year, had an easy time finding them. A tendency to misinterpret helped. Investors complained about test result...

5 days ago · zacks.com

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates.

6 days ago · seekingalpha.com

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Brittany Chaves - Senior Manager of Investor Relations John Leonard - President a...

5 days ago · zacks.com

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.06 per share a year ago.

1 week ago · seekingalpha.com

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better position...

1 week ago · zacks.com

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago · zacks.com

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, NTLA broke out above the 50-day moving ave...

1 week ago · fool.com

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood's investing style is bouncing back into fancy. The co-founder, CEO, and investment manager of Ark Invest is winning again.

2 weeks ago · zacks.com

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 392.8% in Intellia Therapeutics (NTLA). While the effectiveness of this highly sought-after metric is questiona...

1 month ago · accessnewswire.com

Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA

NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal sec...

Load More News